P. Van-der-bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De-plaen et al., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, vol.254, pp.1643-1647, 1991.

S. A. Rosenberg and M. E. Dudley, Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes, Proc. Natl. Acad. Sci. USA, vol.101, issue.2, pp.14639-14645, 2004.

C. J. Melief, S. H. Van-der, and . Burg, Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines, Nat. Rev. Cancer, vol.8, pp.351-360, 2008.

J. L. Chen, P. R. Dunbar, U. Gileadi, E. Jäger, S. Gnjatic et al., Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL, J. Immunol, vol.165, pp.948-955, 2000.

S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola et al., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat. Med, vol.4, pp.321-327, 1998.

D. Valmori, V. Dutoit, D. Liénard, D. Rimoldi, M. J. Pittet et al., Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients, Cancer Res, vol.60, pp.4499-4506, 2000.

D. Valmori, J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Liénard et al., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J. Immunol, vol.160, pp.1750-1758, 1998.

M. Iero, P. Filipazzi, C. Castelli, F. Belli, R. Valdagni et al., Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?, Cancer Immunol. Immunother, vol.58, pp.1159-1167, 2009.

D. E. Speiser, P. Baumgaertner, V. Voelter, E. Devevre, C. Barbey et al., Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen, Proc. Natl. Acad. Sci. USA, vol.105, pp.3849-3854, 2008.

M. S. Bijker, S. J. Van-den-eeden, K. L. Franken, C. J. Melief, R. Offringa et al., CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity, J. Immunol, vol.179, pp.5033-5040, 2007.

F. Faure, A. Mantegazza, C. Sadaka, C. Sedlik, F. Jotereau et al., Long-lasting cross-presentation of tumor antigen in human DC, Eur. J. Immunol, vol.39, pp.380-390, 2009.

W. M. Kast, L. Roux, J. Curren, H. J. Blom, A. C. Voordouw et al., Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide, Proc. Natl. Acad. Sci. USA, vol.88, pp.2283-2287, 1991.

H. Benlalam, V. Vignard, A. Khammari, A. Bonnin, Y. Godet et al., Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients, Cancer Immunol. Immunother, vol.56, pp.515-526, 2007.

M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu et al., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, vol.298, pp.850-854, 2002.

A. Khammari, N. Labarrière, V. Vignard, J. M. Nguyen, M. C. Pandolfino et al., Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones, J. Invest. Dermatol, vol.129, pp.2835-2842, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-02481977

R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang et al., Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, vol.314, pp.126-129, 2006.

V. Vignard, B. Lemercier, A. Lim, M. C. Pandolfino, Y. Guilloux et al., Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells, J. Immunol, vol.175, pp.4797-4805, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-02482064

C. Alanio, F. Lemaitre, H. K. Law, M. Hasan, and M. L. Albert, Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies, Blood, vol.115, pp.3718-3725, 2010.
URL : https://hal.archives-ouvertes.fr/pasteur-01402100

N. Gervois, Y. Guilloux, E. Diez, and F. Jotereau, Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHCtumor peptide interactions, J. Exp. Med, vol.183, pp.2403-2407, 1996.

M. Bodinier, M. A. Peyrat, C. Tournay, F. Davodeau, F. Romagne et al., Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat. Med, vol.6, pp.707-710, 2000.

M. H. Newberg, D. H. Smith, S. B. Haertel, D. R. Vining, E. Lacy et al., Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules, J. Immunol, vol.156, pp.2473-2480, 1996.

L. Derré, M. Ferber, C. Touvrey, E. Devevre, V. Zoete et al., A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide, J. Immunol, vol.179, pp.7635-7645, 2007.

D. Valmori, J. F. Fonteneau, S. Valitutti, N. Gervois, R. Dunbar et al., Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues, Int. Immunol, vol.11, pp.1971-1980, 1999.

T. R. Mempel, S. E. Henrickson, and U. H. Von-andrian, T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases, Nature, vol.427, pp.154-159, 2004.

J. L. Chen, G. Stewart-jones, G. Bossi, N. M. Lissin, L. Wooldridge et al., Structural and kinetic basis for heightened immunogenicity of T cell vaccines, J. Exp. Med, vol.201, pp.1243-1255, 2005.

G. Bioley, C. Jandus, S. Tuyaerts, D. Rimoldi, W. W. Kwok et al., Melan-A/ MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers, J. Immunol, vol.177, pp.6769-6779, 2006.

B. León, M. López-bravo, and C. Ardavín, Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania, Immunity, vol.26, pp.519-531, 2007.

J. Mouriès, G. Moron, G. Schlecht, N. Escriou, G. Dadaglio et al., Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation, Blood, vol.112, pp.3713-3722, 2008.

V. Dutoit, V. Rubio-godoy, M. J. Pittet, A. Zippelius, P. Y. Dietrich et al., Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans, J. Exp. Med, vol.196, pp.207-216, 2002.

M. J. Pittet, A. Zippelius, D. Valmori, D. E. Speiser, J. C. Cerottini et al., Melan-A/MART-1-specific CD8 T cells: from thymus to tumor, Trends Immunol, vol.23, pp.325-328, 2002.

M. Ayyoub, A. Zippelius, M. J. Pittet, D. Rimoldi, D. Valmori et al., Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1, Clin. Cancer Res, vol.9, pp.669-677, 2003.

S. H. Van-der-burg and C. J. Melief, Therapeutic vaccination against human papilloma virus induced malignancies, Curr. Opin. Immunol, vol.23, pp.252-257, 2011.

G. G. Kenter, M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van-der-meer et al., Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia, N. Engl. J. Med, vol.361, pp.1838-1847, 2009.

M. J. Welters, G. G. Kenter, P. J. De-vos-van-steenwijk, M. J. Löwik, D. M. Berends-van-der-meer et al., Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses, Proc. Natl. Acad. Sci. USA, vol.107, pp.11895-11899, 2010.

S. A. Rosenberg and M. E. Dudley, Adoptive cell therapy for the treatment of patients with metastatic melanoma, Curr. Opin. Immunol, vol.21, pp.233-240, 2009.

S. A. Rosenberg, J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes et al., Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy, Clin. Cancer Res, vol.17, pp.4550-4557, 2011.

M. F. Kotturi, I. Scott, T. Wolfe, B. Peters, J. Sidney et al., Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance, J. Immunol, vol.181, pp.2124-2133, 2008.